Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alterity Therapeutics ( (ATHE) ) has shared an announcement.
On May 19, 2026, Alterity Therapeutics reported new clinical and imaging data for ATH434 in Multiple System Atrophy, presented across three medical conferences, which collectively support advancing the candidate to Phase 3 development. Analyses from its Phase 2 trial, including MRI-based quantitative susceptibility mapping and cerebrospinal fluid neurofilament light levels, showed statistically significant slowing of functional decline, reduced iron accumulation in key brain regions, and improved swallowing outcomes, positioning ATH434 as a promising potential first disease-modifying therapy for MSA and reinforcing Alterity’s plans for an End-of-Phase 2 FDA meeting in mid-2026.
The most recent analyst rating on (ATHE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
The score is primarily constrained by weak financial performance—ongoing losses and negative cash flows—despite strong gross margins and revenue growth. Technicals are modestly supportive but not strongly trending, and valuation is pressured by unprofitability and no dividend.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease‑modifying treatments for neurodegenerative disorders, with a particular emphasis on Multiple System Atrophy and Parkinsonian conditions. Its lead oral candidate, ATH434, is designed as an iron chaperone to reduce abnormal brain iron accumulation and protein aggregation, and has secured Fast Track status in the U.S. and orphan drug designations in both the U.S. and Europe for MSA.
Average Trading Volume: 18,871
Technical Sentiment Signal: Buy
Current Market Cap: $77.7M
Find detailed analytics on ATHE stock on TipRanks’ Stock Analysis page.